While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Once-weekly cagrilintide–semaglutide combination therapy produced unprecedented weight reductions in adults with overweight or obesity, with 60% achieving ≥20% loss and strong cardiometabolic benefits ...

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type ...

Novo Nordisk shares fell due to a supply issue in the US, disappointing trial results for its new weight loss drug CagriSema, and heightened competition. The trust declared an interim dividend of 1.4p ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

Grey market grows for cheap weight-loss drugs imported from China Some users try small doses of substances not yet approved ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

Eli Lilly is a leader in the weight management market, with only a single worthy challenger. The pharmaceutical giant has a ...

Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide — are now available in the Indian market. Here’s how they work, how ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...